title: Risk modification for diabetic patients. Are other risk factors treated as diligently as glycemia?
abstract: BACKGROUND
  The importance of glucose control is recognized both by patients with diabetes and their physicians. However, other preventative interventions, such as using medications to manage lipid and blood pressure levels, are underused for diabetic patients.
  
  
  OBJECTIVE
  To determine whether patients with diligent glucose management are more likely to use medications that treat lipids and blood pressure.
  
  
  METHODS
  Administrative data records were evaluated for all diabetic patients aged 65 or older residing in Ontario in 1999 without pre-existing coronary artery disease (n=161,553). Measures of diligent glucose management were insulin use and frequent capillary glucose testing ((3) 2 per day). Outcomes were prescription of a lipid-lowering drug or antihypertensive drug. Using multivariate modeling, odds ratios for each diligence measure were determined for each outcome, adjusting for age, sex, comorbidities, and other covariates.
  
  
  RESULTS
  Patients using insulin did not have a clinically important difference in lipid-lowering drug use (adjusted odds ratio 0.9, 99% confidence interval 0.9 - 1.0, P=0.002) or antihypertensive drug use (adjusted odds ratio 1.1, 99% confidence interval 1.0 - 1.1, P<0.001) versus non-users. Adjusted odds ratios for frequent glucose testing were not significantly different from unity for either lipid-lowering or antihypertensive drug use.
  
  
  CONCLUSIONS
  Patients who required and were capable of diligent glucose management, which is invasive, expensive and time-consuming, were no more likely to use medications to control lipids or blood pressure. Preventative care for patients with diabetes may be too focused on glycemic control, and may be neglecting the management of other cardiovascular risk factors.
authors.affiliation: Department of Medicine and Clinical Epidemiology and Health Care Research Program, University of Toronto, Institute for Clinical Evaluative Sciences. baiju.shah@ices.on.ca
authors.forename: Baiju R
authors.initials: BR
authors.lastname: Shah
authors.forename: Muhammad
authors.initials: M
authors.lastname: Mamdani
authors.forename: Liisa
authors.initials: L
authors.lastname: Jaakkimainen
authors.forename: Janet E
authors.initials: JE
authors.lastname: Hux
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003430:Cross-Sectional Studies; D016208:Databases, Factual; D048909:Diabetes Complications / Q000188:drug therapy / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004363:Drug Utilization; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D009864:Ontario; D010349:Patient Compliance; D020379:Risk Adjustment; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin